Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

, REGN

Regeneron

$373.47

-12.58 (-3.26%)

07:01
10/13/16
10/13
07:01
10/13/16
07:01

Ocular Therapeutix announces strategic collaboration agreement with Regeneron

Ocular Therapeutix (OCUL) announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc. (REGN). Ocular and Regeneron will collaborate on the development of a sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. This formulation is currently in preclinical development. Regeneron's aflibercept is currently approved by the U.S. Food and Drug Administration for certain indications under the brand name EYLEA. Under the terms of the agreement, Ocular Therapeutix and Regeneron will aim to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development. Regeneron has the option to obtain an exclusive license to use Ocular Therapeutix's hydrogel-based technology for the development and commercialization of a sustained release formulation of aflibercept and other biologics targeting VEGF for ophthalmic indications. Ocular Therapeutix will retain all rights to develop its sustained-release hydrogel-based drug delivery platform with all other non-VEGF targeting compounds as well as with small molecule pharmaceuticals, including TKIs, for other retinal diseases. Upon exercising of the option, Ocular Therapeutix would receive a payment of $10 million from Regeneron and Ocular Therapeutix would be responsible for funding development through Phase 1. Regeneron would be responsible for any subsequent development and commercialization costs. Ocular Therapeutix would be eligible to receive up to $305 million in milestone payments from Regeneron for a sustained release version of aflibercept containing Ocular Therapeutix's sustained release hydrogel depot, comprised of up to $155 million in development and regulatory milestone payments, $100 million for the first commercial sale and up to $50 million in commercial milestone payments. In addition, Ocular Therapeutix is eligible to receive tiered high single-digit to low-to-mid teen-digit royalties on potential future net sales.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

  • 30

    Oct

  • 04

    Nov

  • 29

    Nov

  • 29

    Mar

OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

TODAY'S FREE FLY STORIES

02:35
06/29/17
06/29
02:35
06/29/17
02:35
General news
FX Action: The dollar and yen have weakened against most currencies »

FX Action: The dollar and…

RAD

Rite Aid

$3.93

0.19 (5.08%)

, WBA

Walgreens Boots Alliance

$77.09

-0.17 (-0.22%)

20:25
06/28/17
06/28
20:25
06/28/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

RAD

Rite Aid

$3.93

0.19 (5.08%)

WBA

Walgreens Boots Alliance

$77.09

-0.17 (-0.22%)

MKC

McCormick

$98.95

0.42 (0.43%)

LNN

Lindsay

$88.04

1.44 (1.66%)

GBX

Greenbrier

$50.00

0.55 (1.11%)

CAG

Conagra Brands

$37.37

0.37 (1.00%)

STZ

Constellation Brands

$183.68

1.4 (0.77%)

AYI

Acuity Brands

$179.73

4.4 (2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 07

    Jul

FUL

H.B. Fuller

$53.67

1.59 (3.05%)

19:53
06/28/17
06/28
19:53
06/28/17
19:53
Earnings
H.B. Fuller narrows FY17 adjusted EPS to $2.57-$2.67 from $2.57-$2.77 »

EPS consensus $2.66.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

FUL

H.B. Fuller

$53.67

1.59 (3.05%)

19:51
06/28/17
06/28
19:51
06/28/17
19:51
Earnings
H.B. Fuller reports Q2 adjusted EPS 62c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

NERV

Minerva

$7.95

-0.65 (-7.56%)

19:46
06/28/17
06/28
19:46
06/28/17
19:46
Syndicate
Minerva 5M share Secondary priced at $7.75 »

Citi and Jefferies acted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

GOV

Government Properties

$19.33

-2.565 (-11.72%)

19:45
06/28/17
06/28
19:45
06/28/17
19:45
Syndicate
Government Properties 25M share Secondary priced at $18.50 »

Citi, BofA/Merrill,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

APRN

Blue Apron

19:41
06/28/17
06/28
19:41
06/28/17
19:41
Syndicate
Blue Apron 30M share IPO priced at $10.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

SO

Southern Company

$49.15

-0.25 (-0.51%)

, TOSBF

Toshiba, also use TOSYY

$2.57

-0.03 (-1.15%)

19:29
06/28/17
06/28
19:29
06/28/17
19:29
Hot Stocks
Georgia Power, Southern Nuclear to assume Vogtle project management by late July »

Georgia Power (SO) and…

SO

Southern Company

$49.15

-0.25 (-0.51%)

TOSBF

Toshiba, also use TOSYY

$2.57

-0.03 (-1.15%)

TOSYY

Toshiba, also use TOSBF

$15.28

-0.39 (-2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$199.62

0.73 (0.37%)

, BDRBF

Bombardier

$1.87

0.039 (2.13%)

19:29
06/28/17
06/28
19:29
06/28/17
19:29
Periodicals
Boeing requests delay in ruling on Bombardier complaint, Reuters says »

Boeing (BA) has requested…

BA

Boeing

$199.62

0.73 (0.37%)

BDRBF

Bombardier

$1.87

0.039 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BAC

Bank of America

$23.88

0.61 (2.62%)

, BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

19:22
06/28/17
06/28
19:22
06/28/17
19:22
Periodicals
Berkshire may swap Bank of America preferred shares after CCAR news, WSJ says »

After Bank of America…

BAC

Bank of America

$23.88

0.61 (2.62%)

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WATT

Energous

$15.39

0.16 (1.05%)

, DLGNF

Dialog Semiconductor

19:01
06/28/17
06/28
19:01
06/28/17
19:01
Hot Stocks
Dialog invests extra $15M in Energous »

Energous (WATT) announced…

WATT

Energous

$15.39

0.16 (1.05%)

DLGNF

Dialog Semiconductor

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$187.92

0.51 (0.27%)

18:59
06/28/17
06/28
18:59
06/28/17
18:59
Periodicals
Anthem to curtail plan offerings in most of Nevada, WSJ reports »

Anthem plans to stop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$93.77

0.97 (1.05%)

18:36
06/28/17
06/28
18:36
06/28/17
18:36
Hot Stocks
VeriSign says renews .net control through 2023 »

VeriSign disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$81.28

0.59 (0.73%)

, DOW

Dow Chemical

$63.25

0.62 (0.99%)

18:34
06/28/17
06/28
18:34
06/28/17
18:34
Hot Stocks
DuPont, Dow Chemical boards reiterate support of merger agreement »

Dow Chemical Company…

DD

DuPont

$81.28

0.59 (0.73%)

DOW

Dow Chemical

$63.25

0.62 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TPX

Tempur Sealy

$50.87

0.07 (0.14%)

18:33
06/28/17
06/28
18:33
06/28/17
18:33
Hot Stocks
Tempur Sealy enters standstill pact with H Partners, board member Nabi »

Tempur Sealy disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

, DK

Delek US

$26.43

0.25 (0.95%)

18:26
06/28/17
06/28
18:26
06/28/17
18:26
Hot Stocks
Alon USA Energy stockholders approve Delek US merger »

Alon USA Energy (ALJ)…

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

DK

Delek US

$26.43

0.25 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

, CST

CST Brands

18:25
06/28/17
06/28
18:25
06/28/17
18:25
Hot Stocks
Alimentation Couche-Tard confirms closing of CST Brands acquisition »

Alimentation Couche-Tard…

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

CST

CST Brands

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$50.60

0.92 (1.85%)

18:04
06/28/17
06/28
18:04
06/28/17
18:04
Hot Stocks
BNY Mellon announces strategic alliance with One Investment Group »

BNY Mellon and One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

PRGS

Progress Software

$30.82

0.74 (2.46%)

, WOR

Worthington

$47.36

2 (4.41%)

18:03
06/28/17
06/28
18:03
06/28/17
18:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

PRGS

Progress Software

$30.82

0.74 (2.46%)

WOR

Worthington

$47.36

2 (4.41%)

GEMP

Gemphire Therapeutics

$12.27

0.43 (3.63%)

NXTD

Nxt-ID

$1.66

0.2505 (17.77%)

KLIC

Kulicke & Soffa

$20.02

0.53 (2.72%)

SRPT

Sarepta

$33.86

0.83 (2.51%)

SPLS

Staples

$9.93

0.77 (8.41%)

FITB

Fifth Third

$25.49

0.4 (1.59%)

DFS

Discover

$61.88

0.81 (1.33%)

STI

SunTrust

$56.09

0.88 (1.59%)

C

Citi

$65.18

0.95 (1.48%)

RF

Regions Financial

$14.09

0.09 (0.64%)

BK

BNY Mellon

$50.60

0.92 (1.85%)

JPM

JPMorgan

$89.82

1.77 (2.01%)

CFG

Citizens Financial

$35.34

0.5 (1.44%)

BAC

Bank of America

$23.88

0.61 (2.62%)

MS

Morgan Stanley

$44.32

0.1 (0.23%)

WFC

Wells Fargo

$54.33

1.17 (2.20%)

PNC

PNC Financial

$123.40

2.28 (1.88%)

ZION

Zions Bancorp

$42.97

0.43 (1.01%)

GS

Goldman Sachs

$223.22

2.94 (1.33%)

AXP

American Express

$83.97

0.89 (1.07%)

USB

U.S. Bancorp

$51.98

0.84 (1.64%)

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

BLCM

Bellicum Pharmaceuticals

$13.32

0.18 (1.37%)

AKBA

Akebia

$15.50

-0.19 (-1.21%)

DOC

Physicians Realty Trust

$21.60

0.08 (0.37%)

CRZO

Carrizo Oil & Gas

$15.61

-0.47 (-2.92%)

COF

Capital One

$82.98

1.6 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 25

    Jul

  • 26

    Jul

  • 03

    Aug

  • 26

    Sep

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 30

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

VRX

Valeant

$17.15

0.5 (3.00%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Salix confirms FDA accepts NDA for PLENVU »

Valeant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

NTNX

Nutanix

$20.36

1.72 (9.23%)

, GOOG

Alphabet

$940.49

13.16 (1.42%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Nutanix announces strategic alliance with Google Cloud »

Nutanix (NTNX) announced…

NTNX

Nutanix

$20.36

1.72 (9.23%)

GOOG

Alphabet

$940.49

13.16 (1.42%)

GOOGL

Alphabet Class A

$961.01

12.92 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

CE

Celanese

$93.42

0.62 (0.67%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Celanese increases price of Dibutyl Maleate and Dioctyl Maleate in Europe »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$223.22

2.94 (1.33%)

18:00
06/28/17
06/28
18:00
06/28/17
18:00
Hot Stocks
Goldman Sachs: Fed did not object to capital plan »

Goldman Sachs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 17

    Oct

COLB

Columbia Banking

$39.35

0.49 (1.26%)

17:56
06/28/17
06/28
17:56
06/28/17
17:56
Hot Stocks
Columbia Banking names Hadley Robbins CEO »

Columbia Banking System…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFBK

Northfield Bancorp

$17.36

0.3 (1.76%)

17:55
06/28/17
06/28
17:55
06/28/17
17:55
Hot Stocks
Northfield Bancorp CEO John Alexander to retire, Steven Klein to succeed »

Northfield Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.